Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio

Cancer

Volumn 120, Issue 21, 2014, Pages 3346-3352

  Templeton, Arnoud J ^a   Pezaro, Carmel ^b   Omlin, Aurelius ^b   McNamara, Mairéad G ^a   Leibowitz Amit, Raya ^a   Vera Badillo, Francisco E ^a   Attard, Gerhardt ^b   De Bono, Johann S ^b   Tannock, Ian F ^a   Amir, Eitan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

castration resistant prostate cancer, neutrophil to lymphocyte ratio; prognosis; score

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; VALIDATION PROCESS; VERY ELDERLY; BLOOD; LYMPHOCYTE; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84915734431     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28890     Document Type: Article

References (25)

1. Lughezzani G, Briganti A, Karakiewicz PI, et al., Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010; 58: 687-700.
2. Halabi S, Small EJ, Kantoff PW, et al., Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21: 1232-1237.
3. Smaletz O, Scher HI, Small EJ, et al., Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002; 20: 3972-3982.
4. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007; 13: 6396-6403.
5. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S,. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010; 46: 517-525.
6. Halabi S, Lin CY, Kelly WK, et al., Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32: 671-677.
7. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
8. Templeton AJ, McNamara MG, Vera-Badillo FE, et al., Prognostic role of neutrophil to lymphocyte ratio (nlr) in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014: 106; dju124.
9. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ,. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88: 218-230.
10. Sonpavde G, Pond GR, Clarke SJ, et al., Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. J Clin Oncol. 2012; 30:(suppl; abstr 4644).
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005; 41: 1690-1696.
12. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS,. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. 2012; 15: 195-201.
13. Sonpavde G, Pond GR, Armstrong AJ, et al., Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014; S1558-7673:00054-00058.
14. Keizman D, Gottfried M, Ish-Shalom M, et al., Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 2012; 17: 1508-1514.
15. Leibowitz-Amit R, Templeton AJ, Omlin A, et al., Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014; 25: 657-662.
16. McMillan DC,. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39: 534-540.
17. Ryan CJ, Molina A, Li J, et al., Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013; 31: 2791-2798.
18. Kalin M, Cima I, Schiess R, et al., Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur Urol. 2011; 60: 1235-1243.
19. Lara PN, Jr,., Ely B, Quinn DI, et al., Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421. J Natl Cancer Inst. 2014;106:dju013.
20. Levesque E, Huang SP, Audet-Walsh E, et al., Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clin Cancer Res. 2013; 19: 699-709.
21. de Bono JS, Scher HI, Montgomery RB, et al., Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14: 6302-6309.
22. Bhat T, Teli S, Rijal J, et al., Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013; 11: 55-59.
23. de Bono JS, Oudard S, Ozguroglu M, et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154.
24. Scher HI, Fizazi K, Saad F, et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-1197.
25. Parker C, Nilsson S, Heinrich D, et al., Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369: 213-223.